|Bid||8.31 x 800|
|Ask||9.15 x 800|
|Day's Range||9.10 - 9.93|
|52 Week Range||3.26 - 11.52|
|Beta (5Y Monthly)||1.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.00|
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,250,000 American Depositary Shares (ADSs) of the Company, at a price to the public of $8.00 per ADS, less underwriting discounts and commissions. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. The closing of the offering is expected to occur on or about March 4, 2021, subject to satisfaction of customary closing conditions.
Following the FDA review of data from the U.S. Phase 2 study of opaganib and receipt of its recommendations, RedHill Biopharma Ltd (NASDAQ: RDHL) plans to expand its global Phase 2/3 study of opaganib in patients with severe COVID-19 to the U.S. The study's expansion to the U.S. will help further speed-up enrollment, expand the study to eight countries and approximately 40 recruiting sites. The 464-patient study is over 50% enrolled, and topline data expected in the second quarter of 2021. The global Phase 2/3 study recently underwent a positive DSMB futility review, which is suggestive that the study has the potential for a positive outcome. In December last year, the company announced positive topline data from the non-powered U.S. Phase 2 study with opaganib in patients with COVID-19 pneumonia and demonstrated positive safety and efficacy signals. Opaganib is an orally-administered sphingosine kinase-2 (SK2) inhibitor with demonstrated antiviral, anti-inflammatory, and anti-thrombotic activity that targets a human cell component involved in viral replication. Price Action: RDHL shares are down 3.0397% at $10.95 in the premarket trading on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaRedHill Biopharma, Cosmo Pharma In Manufacturing Pact for Movantik, RHB-204© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its plans to expand the Company's global Phase 2/3 study of opaganib in patients with severe COVID-19 to the U.S., following U.S. Food and Drug Administration (FDA) review of the data from the U.S. Phase 2 study of opaganib and receipt of its recommendations.